UN Negotiating Price of Takeda’s New Dengue Vaccine

April 28th, 2023|Categories: Featured, Industry News|Tags: , , , , |

The World Health Organization’s (WHO’s) Pan American Health Organization (PAHO) is working with Takeda to negotiate pricing for the manufacturer’s new dengue vaccine Qdenga, the only one for the widespread illness. A key strategy being proposed is that large nations can pool their resources to purchase the vaccines in bulk at a lower price.

FDA Plans to Authorize Additional Omicron Booster for Select Populations

April 4th, 2023|Categories: Featured, Industry News|Tags: , , , |

A report by the Washington Post indicates that the US Food and Drug Administration is set to approve another round of boosters for adults 65 and up. The approval will also include adults who are immunocompromised. Boosters will be available for these patients for free 4 months after their last booster.

Takeda Reveals Pricing for Dengue Vaccine

March 21st, 2023|Categories: Featured, Industry News|Tags: , , , , |

Fresh off approval of its dengue vaccine in Brazil, Takeda has announced its pricing strategy for the shot. Prices will be determined by endemic status of the disease in a given country. Indonesia, where the virus is endemic, will see the vaccine priced at $40 per dose, while travel markets like Germany will pay $115 a shot.

Moderna Optimistic About Cancer Vaccine Getting Accelerated Approval

March 7th, 2023|Categories: Featured, Industry News|Tags: , , , , |

Moderna’s president Stephen Hoge told attendees at Cowen’s Annual Healthcare Conference that the company is optimistic about its chances to snag accelerated approval for its mRNA-based personalized cancer vaccine. Hoge pointed out that data from December may not be enough, but there is enough time to generate new data that may tip the scales.

Monkeypox Vaccines May Be Real-World Data’s Time to Shine

October 25th, 2022|Categories: Featured, Industry News|Tags: , , , |

Real-world data (RWD) played a pivotal role in the rapid development and regulatory approval process for the current slate of COVID-19 vaccines. Similarly, the development and timely rollout of monkeypox vaccines depends on RWD. For example, RWD is helping inform the move to intradermal injection of Bavarian Nordic’s Jynneos vaccine to help stretch limited supplies.

Biden Declares Pandemic is Over – Vaccine Stocks Take a Hit

September 20th, 2022|Categories: Featured, Industry News|Tags: , , , , |

US President Joe Biden declared the pandemic ‘over’ in a “60 Minutes” interview this Sunday, September 18th. In response, many vaccine manufacturers saw a drop in share prices, including Moderna, Novavax, and BioNTech. This reflects a larger dip in the biotech market, particularly companies working with COVID-19 therapeutics.

South African Biotech Biovac Produces First Batch of COVID-19 Vaccine

September 19th, 2022|Categories: Featured, Industry News|Tags: , , , , |

Biovac, a vaccine producer located in South Africa, has produced its first batch of Pfizer and BioNTech’s mRNA vaccine. The company was added to Pfizer and BioNTech’s vaccine manufacturing network just over a year ago. The South African Health Regulatory Products Authority still needs to inspect the vaccines before they can be distributed.

UK MHRA Approves Novavax COVID-19 for Ages 12-17

August 31st, 2022|Categories: Featured, Industry News|Tags: , , , |

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has given expanded conditional marketing authorization (CMA) to use the Novavax COVID-19 vaccine in people ages 12-17. The decision was made based on data from the PREVENT-19 phase 3 trial. Early data showed that it had an 80% clinical efficacy during the US’s delta wave.

Bavarian Nordic Boosts Production of Monkeypox Vaccine

August 24th, 2022|Categories: Featured, Industry News|Tags: , , , , |

Paul Chaplin, CEO Bavarian Nordic announced during a call with investors that the company has leaned heavily into production of bulk Jynneos, its monkeypox vaccine. The news comes shortly after the company made a deal with Grand River Aseptic Manufacturing to fill vials from bulk vaccine in the US. Bavarian Nordic is now dedicating all of its production capacity to Jynneos, sidelining its other vaccines

Icosavax Identifies Reason its COVID-19 Vaccine Failed, Looks Toward Future

July 29th, 2022|Categories: Featured, Industry News|Tags: , , , |

Icosavax has just wrapped up an investigation into the disappointing results of its COVID-19 vaccine candidate, IVX-411, finding that instability issues were at fault. The receptor binding domain of the soccer ball-shaped “virus-like particle” degraded at the recommended storage temps of 2-8°C. The instability proved to diminish the effect of the vaccine in mice studies. 

Go to Top